观点：勇者胜。 - Suppr

Perspective: Who dares, wins.

作者信息

Bielekova Bibi

机构信息

Intramural Research Program of the US National Institute of Neurological Disorders and Stroke in Bethesda, Maryland, which supports her research programme.

出版信息

Nature. 2016 Nov 30;540(7631):S10. doi: 10.1038/540S10a.

DOI:10.1038/540S10a

PMID:27902681

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5708877/

Abstract

摘要

相似文献

Perspective: Who dares, wins.

Nature. 2016 Nov 30;540(7631):S10. doi: 10.1038/540S10a.

Responsiveness and predictive values in PPMS: an uncertain message.

Neurology. 2008 Mar 25;70(13 Pt 2):1061-2. doi: 10.1212/01.wnl.0000306414.53844.50.

Primary progressive MS.

Int MS J. 2003 Aug;10(3):89-95.

Therapies: Progressive steps.

Nature. 2016 Nov 30;540(7631):S7-S9. doi: 10.1038/540S7a.

CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2021 Sep 8;8(6). doi: 10.1212/NXI.0000000000001082. Print 2021 Nov.

[Regulatory science on biomarker usage for development and proper use of drugs].

Yakugaku Zasshi. 2015;135(5):647-8. doi: 10.1248/yakushi.14-00230-F.

Primary progressive multiple sclerosis: increasing clarity but many unanswered questions.

J Neurol Sci. 2002 Jul 15;199(1-2):1-15. doi: 10.1016/s0022-510x(02)00053-9.

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.

Trends Pharmacol Sci. 2016 Oct;37(10):808-810. doi: 10.1016/j.tips.2016.07.005. Epub 2016 Aug 20.

Inclusion criteria used in trials of people with progressive multiple sclerosis.

Mult Scler. 2020 Mar;26(3):279-283. doi: 10.1177/1352458518803769. Epub 2018 Oct 15.

Multiple sclerosis: progression rate and severity in a multicenter cohort from Algeria.

Mult Scler. 2014 Dec;20(14):1923-4. doi: 10.1177/1352458514543343. Epub 2014 Aug 13.

引用本文的文献

The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.

Biomedicines. 2022 Aug 28;10(9):2099. doi: 10.3390/biomedicines10092099.

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Semin Pediatr Neurol. 2017 Aug;24(3):229-239. doi: 10.1016/j.spen.2017.08.001. Epub 2017 Aug 12.

Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Front Neurol. 2017 Sep 11;8:468. doi: 10.3389/fneur.2017.00468. eCollection 2017.

本文引用的文献

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Front Neurol. 2016 Aug 15;7:131. doi: 10.3389/fneur.2016.00131. eCollection 2016.

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):166-79. doi: 10.1002/acn3.293. eCollection 2016 Mar.

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Ann Clin Transl Neurol. 2015 May;2(5):445-55. doi: 10.1002/acn3.181. Epub 2015 Apr 7.

The economic cost of brain disorders in Europe.

Eur J Neurol. 2012 Jan;19(1):155-62. doi: 10.1111/j.1468-1331.2011.03590.x.

Can the pharmaceutical industry reduce attrition rates?

Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Perspective: Who dares, wins.

作者信息

Bielekova Bibi

机构信息

Intramural Research Program of the US National Institute of Neurological Disorders and Stroke in Bethesda, Maryland, which supports her research programme.

出版信息

Nature. 2016 Nov 30;540(7631):S10. doi: 10.1038/540S10a.

DOI:10.1038/540S10a

PMID:27902681

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5708877/

Abstract

摘要

相似文献

Perspective: Who dares, wins.

Nature. 2016 Nov 30;540(7631):S10. doi: 10.1038/540S10a.

Responsiveness and predictive values in PPMS: an uncertain message.

Neurology. 2008 Mar 25;70(13 Pt 2):1061-2. doi: 10.1212/01.wnl.0000306414.53844.50.

Primary progressive MS.

Int MS J. 2003 Aug;10(3):89-95.

Therapies: Progressive steps.

Nature. 2016 Nov 30;540(7631):S7-S9. doi: 10.1038/540S7a.

CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2021 Sep 8;8(6). doi: 10.1212/NXI.0000000000001082. Print 2021 Nov.

[Regulatory science on biomarker usage for development and proper use of drugs].

Yakugaku Zasshi. 2015;135(5):647-8. doi: 10.1248/yakushi.14-00230-F.

Primary progressive multiple sclerosis: increasing clarity but many unanswered questions.

J Neurol Sci. 2002 Jul 15;199(1-2):1-15. doi: 10.1016/s0022-510x(02)00053-9.

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.

Trends Pharmacol Sci. 2016 Oct;37(10):808-810. doi: 10.1016/j.tips.2016.07.005. Epub 2016 Aug 20.

Inclusion criteria used in trials of people with progressive multiple sclerosis.

Mult Scler. 2020 Mar;26(3):279-283. doi: 10.1177/1352458518803769. Epub 2018 Oct 15.

Multiple sclerosis: progression rate and severity in a multicenter cohort from Algeria.

Mult Scler. 2014 Dec;20(14):1923-4. doi: 10.1177/1352458514543343. Epub 2014 Aug 13.

引用本文的文献

The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.

Biomedicines. 2022 Aug 28;10(9):2099. doi: 10.3390/biomedicines10092099.

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Semin Pediatr Neurol. 2017 Aug;24(3):229-239. doi: 10.1016/j.spen.2017.08.001. Epub 2017 Aug 12.

Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Front Neurol. 2017 Sep 11;8:468. doi: 10.3389/fneur.2017.00468. eCollection 2017.

本文引用的文献

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Front Neurol. 2016 Aug 15;7:131. doi: 10.3389/fneur.2016.00131. eCollection 2016.

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):166-79. doi: 10.1002/acn3.293. eCollection 2016 Mar.

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Ann Clin Transl Neurol. 2015 May;2(5):445-55. doi: 10.1002/acn3.181. Epub 2015 Apr 7.

The economic cost of brain disorders in Europe.

Eur J Neurol. 2012 Jan;19(1):155-62. doi: 10.1111/j.1468-1331.2011.03590.x.

Can the pharmaceutical industry reduce attrition rates?

Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470.

Perspective: Who dares, wins.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Perspective: Who dares, wins.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献